New weapon tested against aggressive lymphoma that evades standard treatments
NCT ID NCT07369492
Summary
This study is testing a new type of CAR-T cell therapy for adults with a specific, difficult-to-treat form of B-cell lymphoma. The cancer in these patients does not have the CD19 marker, making it unresponsive to many existing CAR-T treatments. The main goal of this early-phase trial is to find a safe and tolerable dose of these new BAFF-R CAR-T cells and to see if they can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.